NCT05214521

Brief Summary

The aim of the study is to investigate the efficacy and safety of digital interactive technology with artificial intelligence and biofeedback Smart glove "SensoRehab" for restoration of in-hand manipulation in patients with ischemic stroke in the early and late recovery periods.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 11, 2021

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

January 14, 2022

Completed
14 days until next milestone

First Posted

Study publicly available on registry

January 28, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2023

Completed
Last Updated

May 17, 2022

Status Verified

May 1, 2022

Enrollment Period

2 years

First QC Date

January 14, 2022

Last Update Submit

May 15, 2022

Conditions

Keywords

post-stroke dysfunction of the handupper limb medical rehabilitationdigital interactive technologyartificial intelligenceischemic stroke rehabilitation

Outcome Measures

Primary Outcomes (4)

  • Fugl-Meyer Upper Extremity Scale (FMA-UE) dynamic

    The FMA UE Scale comprises 33 items, each scored on a scale of0 to 2, where 0 = cannot perform, 1 = performs partially and2 = performs fully. It is free, requires only household items fortesting, and takes up to 30 minutes to administer. Changes in sections A-D of the FMA-UE Scale by 7 points or more are considered as efficacy.

    Baseline, end of the 2-nd week

  • Fugl-Meyer Upper Extremity Scale (FMA-UE) dynamic

    The FMA UE Scale comprises 33 items, each scored on a scale of0 to 2, where 0 = cannot perform, 1 = performs partially and2 = performs fully. It is free, requires only household items fortesting, and takes up to 30 minutes to administer. Changes in sections A-D of the FMA-UE Scale by 7 points or more are considered as efficacy.

    Baseline, 1-month after completing training

  • Action Research Arm Test (ARAT) Scale dynamic

    The Action Research Arm Test (ARAT) is a 19 item observational measures. Items comprising the ARAT are categorized into four subscales (grasp, grip, pinch and gross movement) and arranged in order of decreasing difficulty, with the most difficult task examined first, followed by the least difficult task. Task performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 (movement performed normally). Changes in the total ARAT Scale score by 4 points or more more are considered as efficacy.

    Baseline, end of the 2-nd week

  • Action Research Arm Test (ARAT) Scale dynamic

    The Action Research Arm Test (ARAT) is a 19 item observational measures. Items comprising the ARAT are categorized into four subscales (grasp, grip, pinch and gross movement) and arranged in order of decreasing difficulty, with the most difficult task examined first, followed by the least difficult task. Task performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 (movement performed normally). Changes in the total ARAT Scale score by 4 points or more more are considered as efficacy.

    Baseline, 1-month after completing training

Secondary Outcomes (7)

  • percentage of correctly performed tasks

    Baseline, end of the 2-nd week

  • change in the paresis degree The 6-point Medical Research Council Scale for assessing muscle strength: MRCS

    Baseline, end of the 2-nd week and 1-month after completing training

  • changes in spasticity severity

    Baseline, end of the 2-nd week and 1-month after completing training

  • changes in level of impairment or dependence in daily life

    Baseline, end of the 2-nd week and 1-month after completing training

  • сhanges in cognitive status

    Baseline, end of the 2-nd week and 1-month after completing training

  • +2 more secondary outcomes

Study Arms (1)

digital interactive technology Smart glove "SensoRehab"

EXPERIMENTAL

The operation of the digital interactive complex Smart glove "SensoRehab" is based on the visual and kinesthetic (proprioceptive) biofeedback principle by using a set of cognitive interactive computer games controlled by finger and hand movements. The technique involves neurosensory training and retraining to improve the fine use of the hand and arm, and the patient's cognitive and emotional state.

Device: digital interactive technology Smart glove "SensoRehab"

Interventions

Participants will receive rehabilitation program including sessions on the Smart glove "SensoRehab" (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks.

digital interactive technology Smart glove "SensoRehab"

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men or women aged 18 to 70 years after a first-onset IS, early (1-6 months), late recovery (6-12 months) periods.
  • Supratentorial IS according to MRI of the brain.
  • The severity of UL paresis ranged from a score of 4 to 3 according to the Medical Research Council Scale (MRCS).20
  • Spasticity of 2 points or less by the Modified Ashworth Scale (MAS)
  • Cognitive function more than 20 points on the Montreal Cognitive Assessment (MoCA)
  • Affective disorders score less than 11 on the Hospital Anxiety and Depression Scale (HADS)
  • The patient's ability and willingness to comply with the requirements of this protocol.

You may not qualify if:

  • Concomitant neurological diseases causing decreased muscle strength or increased muscle tone in the UL (e.g., cerebral palsy, brain injury).
  • Clinically significant limitation of the passive movement amplitude in the joints of the investigated hand, pronounced contracture and deformities of the upper extremity.
  • Severe visual impairment, decreased visual acuity of less than 0.2 in the worst eye according to the Golovin-Sivtsev Table24.
  • Sensory aphasia, gross motor aphasia.
  • Recurrent stroke.
  • Unstable angina and/or heart attack in previous month.
  • Uncontrolled arterial hypertension.
  • Somatic diseases in decompensation stage.
  • Any medical condition, including mental disease or epilepsy that could affect the interpretation of study results, the study procedures or patient safety.
  • Pregnancy.
  • Lactation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine, branch 7

Moscow, 105120, Russia

RECRUITING

Study Officials

  • Elena V Kostenko, MD

    Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Liudmila V Petrova, PhD

CONTACT

Elena V Kostenko, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: an open-label observational trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2022

First Posted

January 28, 2022

Study Start

January 11, 2021

Primary Completion

December 30, 2022

Study Completion

December 30, 2023

Last Updated

May 17, 2022

Record last verified: 2022-05

Locations